Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficiency of Vitamin D3 and 25-hydroxyvitamin D3 on Transcriptomic Changes of Low Vitamin D Responders (VitDHiD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03537027
Recruitment Status : Completed
First Posted : May 25, 2018
Last Update Posted : October 12, 2018
Sponsor:
Collaborator:
DSM Nutritional Products, Inc.
Information provided by (Responsible Party):
Carsten Carlberg, University of Eastern Finland

Brief Summary:
The purpose of the study is to investigate in vivo whether a high-dose vitamin D3 oral bolus (2000 micrograms) produces marked vitamin D receptor target gene expression response and whether there is large inter-individual variation. These effects are compared to in vitro treatment of peripheral blood mononuclear cells from these subjects with 25(OH)D.

Condition or disease Intervention/treatment Phase
Vitamin D Receptor Target Gene Expression Serum 25(OH)D Concentration Dietary Supplement: Vitamin D3 Phase 1

Detailed Description:

Serum 25-hydroxyvitamin D3 [25(OH)D3] is a well-established marker for vitamin D status of the human body. In addition to the general importance of vitamin D for bone health, low serum 25(OH)D3 concentrations have been associated with increased risk of several health outcomes, such as autoimmune diseases, type 2 diabetes and cardiovascular complications. However, there is significant inter-individual variation in the average serum 25(OH)D3 concentrations and also in the response to supplementation with vitamin D. Genetic and epigenetic factors have been suggested to be responsible for a large part of the variation, but currently there is little information about the health effects of the variation.

In our previous studies VitDmet (Clinicaltrials.gov NCT01479933) and VitDbol (Clinicaltrials.gov NCT02063334) we showed that the participants can be classified into high, mid and low responders to vitamin D and defined the new biomarker "vitamin D response index". Some 25% of the population seem to be low responders and are under higher risk to suffer from insufficient supplementation with vitamin D. The current study will focus on low vitamin D responders (among the 40 healthy individuals recruited in the study, 20-60 years old), i.e. it will use the same oral vitamin D3 bolus (2,000 µg, i.e. 80,000 IU in one day) as in our VitDbol study, in order to identify low vitamin D responders.

By in vitro treatment of peripheral blood mononuclear cells (PBMCs) of low responders with 25(OH)D3 for 24 h (in comparison to in vitro stimulations with 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and in vivo vitamin D3 supplementation of the same subjects) we will obtain samples that allow the transcriptome-wide investigation of changes in gene expression. The underlying hypothesis of this study is that a stimulation with 25(OH)D3 is more efficient than a treatment with vitamin D3, so that in future low vitamin D responders may be supplemented with 25(OH)D3 rather than with vitamin D3.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Comparing the Efficiency of Vitamin D3 and 25-hydroxyvitamin D3 Treatment on Changes of the Transcriptome of Low Vitamin D Responders
Actual Study Start Date : May 3, 2018
Actual Primary Completion Date : May 31, 2018
Actual Study Completion Date : May 31, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vitamin D3
2000 micrograms of vitamin D3 in two doses during one day
Dietary Supplement: Vitamin D3
In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
Other Name: cholecalciferol




Primary Outcome Measures :
  1. In vivo change from baseline in vitamin D target gene expression in the subjects [ Time Frame: 24 hours after the baseline ]
    Effect of 2000 microgram vitamin D3 dose on the expression of vitamin D receptor target genes

  2. In vitro change from baseline in vitamin D target gene expression in peripheral blood mononuclear cells [ Time Frame: 24 hours after the baseline ]
    Effects of treatment of cells for 24 h with 100 nM of 25(OH)D3, 1 nM of 1,25(OH)2D3 or vehicle (solvent) on the expression of vitamin D receptor target genes


Secondary Outcome Measures :
  1. In vivo change from baseline in serum 25(OH)D concentration [ Time Frame: 24 hours after the baseline ]
    Effect of 2000 microgram vitamin D3 dose on serum 25(OH)D3 concentrations

  2. In vivo change from baseline in serum calcium concentration (safety and tolerability) [ Time Frame: 24 hours after the baseline ]
    Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum calcium concentrations

  3. In vivo change from baseline in serum alanine transaminase concentration (safety and tolerability) [ Time Frame: 24 hours after the baseline ]
    Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum alanine transaminase (ALAT) concentrations

  4. In vivo change from baseline in serum gamma-glutamyl transferase concentration (safety and tolerability) [ Time Frame: 24 hours after the baseline ]
    Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum gamma-glutamyl transferase (GGT) concentrations

  5. In vivo change from baseline in serum creatinine concentration (safety and tolerability) [ Time Frame: 24 hours after the baseline ]
    Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum creatinine concentrations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non-smoking
  • BMI 20-25 kg/m2.

Exclusion Criteria:

  • History of kidney stones, renal failure or dialysis, hypercalcemia, hypo- or hyperparathyroidism, severe liver disease (cirrhosis), or sarcoidosis or other granulomatous diseases, such as active chronic tuberculosis or Wegener's granulomatosis.
  • Continuous use of anti-inflammatory medicines.
  • Regular use of supplements containing over 20 micrograms of vitamin D.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03537027


Locations
Layout table for location information
Finland
University of Eastern Finland
Kuopio, Finland, 70211
Sponsors and Collaborators
University of Eastern Finland
DSM Nutritional Products, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Carsten Carlberg, PhD University of Eastern Finland

Layout table for additonal information
Responsible Party: Carsten Carlberg, Professor of biochemistry, University of Eastern Finland
ClinicalTrials.gov Identifier: NCT03537027     History of Changes
Other Study ID Numbers: VitDHiD
First Posted: May 25, 2018    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Carsten Carlberg, University of Eastern Finland:
vitamin D3
cholecalciferol
calcidiol
25-hydroxyvitamin D
gene expression
vitamin D receptor
adults
clinical trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin D
Ergocalciferols
Cholecalciferol
Hydroxycholecalciferols
Calcifediol
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents